Valuation: Exelixis, Inc.

Market Cap 14.47B 12.74B 12.08B 10.9B 20.55B 1,388B 20.81B 144B 55.6B 709B 54.35B 53.16B 2,274B P/E 2026 *
18x
P/E 2027 * 14.9x
Enterprise Value 13.73B 12.09B 11.45B 10.34B 19.49B 1,316B 19.74B 137B 52.74B 673B 51.55B 50.43B 2,157B EV / Sales 2026 *
5.37x
EV / Sales 2027 * 4.42x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day+4.05%
1 week+8.00%
1 month+14.68%
3 months+13.87%
1 week 47.88
Extreme 47.8755
50.33
1 month 45.44
Extreme 45.4435
50.33
Current year 41.02
Extreme 41.0245
50.33
1 year 41.02
Extreme 41.0245
50.33
3 years 41.02
Extreme 41.0245
50.33
5 years 41.02
Extreme 41.0245
50.33
10 years 41.02
Extreme 41.0245
50.33
Manager TitleAgeSince
Chief Executive Officer 65 22/07/2010
Director of Finance/CFO 58 15/07/2015
Chief Operating Officer 63 01/02/2016
Director TitleAgeSince
Director/Board Member 70 01/02/2004
Director/Board Member 82 01/08/2004
Chairman 77 01/01/1998
Change 5-day change 1-year change 3-year change Capi.($)
+4.05%+8.00% - - 14.47B
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.64%+0.79%+27.21%+80.17% 60.14B
-1.22%-0.63%+5.95%+34.70% 48.15B
-0.05%+0.37%+41.54%+36.65% 44.25B
+0.38%+7.61%+339.53%+641.55% 43.99B
+0.18%+0.26%+7.41%+103.45% 41.61B
-0.67%+0.17%+7.60%+46.37% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-1.29%-3.55%-20.74%+352.04% 24.93B
Average +0.97%+1.53%+54.96%+156.88% 44.09B
Weighted average by Cap. +0.92%+1.53%+59.15%+147.39%

Financials

2026 *2027 *
Net sales 2.55B 2.25B 2.13B 1.92B 3.63B 245B 3.67B 25.5B 9.81B 125B 9.59B 9.38B 401B 2.91B 2.56B 2.42B 2.19B 4.13B 279B 4.18B 29.01B 11.16B 142B 10.91B 10.67B 457B
Net income 821M 723M 685M 618M 1.17B 78.69B 1.18B 8.19B 3.15B 40.23B 3.08B 3.01B 129B 1.01B 891M 845M 763M 1.44B 97.07B 1.46B 10.11B 3.89B 49.62B 3.8B 3.72B 159B
Net Debt -744M -656M -621M -561M -1.06B -71.38B -1.07B -7.43B -2.86B -36.49B -2.8B -2.73B -117B -1.62B -1.43B -1.35B -1.22B -2.3B -156B -2.33B -16.2B -6.23B -79.54B -6.09B -5.96B -255B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change
30/09/26 CHF 50.33 +4.05%
29/09/26 CHF 48.37 -0.42%
28/09/26 CHF 48.57 +1.46%
25/09/26 CHF 47.88 +1.17%
24/09/26 CHF 47.32 +1.54%
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
58.41USD
Average target price
53.93USD
Spread / Average Target
-7.66%

Quarterly revenue - Rate of surprise